These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26433554)

  • 1. The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.
    Schott AF; Welch JJ; Verschraegen CF; Kurzrock R
    Semin Oncol; 2015 Oct; 42(5):731-9. PubMed ID: 26433554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New clinical research strategies for rare gynecologic malignancies.
    Ray-Coquard I; Pujade-Lauraine E; Ledermann JA
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):53-7. PubMed ID: 25490380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The promise and challenges of rare cancer research.
    Komatsubara KM; Carvajal RD
    Lancet Oncol; 2016 Feb; 17(2):136-138. PubMed ID: 26868336
    [No Abstract]   [Full Text] [Related]  

  • 4. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research methods to change clinical practice for patients with rare cancers.
    Billingham L; Malottki K; Steven N
    Lancet Oncol; 2016 Feb; 17(2):e70-e80. PubMed ID: 26868356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications.
    Unger JM; Nghiem VT; Hershman DL; Vaidya R; LeBlanc M; Blanke CD
    JAMA Netw Open; 2019 Sep; 2(9):e1910593. PubMed ID: 31483471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare cancers in children - The EXPeRT Initiative: a report from the European Cooperative Study Group on Pediatric Rare Tumors.
    Bisogno G; Ferrari A; Bien E; Brecht IB; Brennan B; Cecchetto G; Godzinski J; Orbach D; Reguerre Y; Stachowicz-Stencel T; Schneider DT
    Klin Padiatr; 2012 Oct; 224(6):416-20. PubMed ID: 23143769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Globalization of Cooperative Groups.
    Valdivieso M; Corn BW; Dancey JE; Wickerham DL; Horvath LE; Perez EA; Urton A; Cronin WM; Field E; Lackey E; Blanke CD
    Semin Oncol; 2015 Oct; 42(5):693-712. PubMed ID: 26433551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare Tumors in Children: Progress Through Collaboration.
    Pappo AS; Furman WL; Schultz KA; Ferrari A; Helman L; Krailo MD
    J Clin Oncol; 2015 Sep; 33(27):3047-54. PubMed ID: 26304909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.
    Ledermann JA; Ray-Coquard I
    Am Soc Clin Oncol Educ Book; 2014; ():e282-6. PubMed ID: 24857114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of research collaborations and consortia in rare cancers.
    Blay JY; Coindre JM; Ducimetière F; Ray-Coquard I
    Lancet Oncol; 2016 Feb; 17(2):e62-e69. PubMed ID: 26868355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
    Bando H; Takebe N
    Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collaboration is key to treating uncommon cancers: scientists and patients champion research in these rare diseases.
    Printz C
    Cancer; 2010 Jun; 116(12):2847-9. PubMed ID: 20564387
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative.
    Bogaerts J; Sydes MR; Keat N; McConnell A; Benson A; Ho A; Roth A; Fortpied C; Eng C; Peckitt C; Coens C; Pettaway C; Arnold D; Hall E; Marshall E; Sclafani F; Hatcher H; Earl H; Ray-Coquard I; Paul J; Blay JY; Whelan J; Panageas K; Wheatley K; Harrington K; Licitra L; Billingham L; Hensley M; McCabe M; Patel PM; Carvajal R; Wilson R; Glynne-Jones R; McWilliams R; Leyvraz S; Rao S; Nicholson S; Filiaci V; Negrouk A; Lacombe D; Dupont E; Pauporté I; Welch JJ; Law K; Trimble T; Seymour M
    Eur J Cancer; 2015 Feb; 51(3):271-81. PubMed ID: 25542058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Enrollment of Older Adults Onto National Cancer Institute National Clinical Trials Network Trials.
    Mishkin GE; Denicoff AM; Best AF; Little RF
    J Natl Cancer Inst Monogr; 2022 Dec; 2022(60):111-116. PubMed ID: 36519819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial design for rare cancers: why a less conventional route may be required.
    Panageas KS
    Expert Rev Clin Pharmacol; 2015; 8(6):661-3. PubMed ID: 26517109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing Adolescent and Young Adult Oncology Research Within the National Clinical Trials Network: Rationale, Progress, and Emerging Strategies.
    Weiss AR; Nichols CR; Freyer DR
    Semin Oncol; 2015 Oct; 42(5):740-7. PubMed ID: 26433555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The U.S. pediatric cancer clinical trials programmes: international implications and the way forward.
    Bleyer WA
    Eur J Cancer; 1997 Aug; 33(9):1439-47. PubMed ID: 9337687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical rare cancer research to inform clinical trial design.
    Barker HE; Scott CL
    Nat Rev Cancer; 2019 Sep; 19(9):481-482. PubMed ID: 31263218
    [No Abstract]   [Full Text] [Related]  

  • 20. Cooperative Group Trials in the Community Setting.
    Lloyd Wade J; Petrelli NJ; McCaskill-Stevens W
    Semin Oncol; 2015 Oct; 42(5):686-92. PubMed ID: 26433550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.